Intended for healthcare professionals

Letters Reform of Cancer Drugs Fund

New Cancer Drugs Fund solves the wrong problem

BMJ 2016; 355 doi: (Published 26 October 2016) Cite this as: BMJ 2016;355:i5619
  1. Anthony J Hatswell, health economist
  1. BresMed, Sheffield S1 2DW, UK
  1. ahatswell{at}

I agree with the proposal from Grieve and colleagues to allocate money from the Cancer Drugs Fund to randomised studies in place of the collection of observational data, though for different reasons.1

The collection of observational data by the new fund may be helpful in some cases, but in the vast majority it …

View Full Text

Log in

Log in through your institution


* For online subscription